<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342573</url>
  </required_header>
  <id_info>
    <org_study_id>16-006987</org_study_id>
    <nct_id>NCT03342573</nct_id>
  </id_info>
  <brief_title>Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris</brief_title>
  <official_title>Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the potential effectiveness of Cosentyx in
      the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cosentyx (Secukinumab) for the treatment of adult onset pityriasis rubra pilaris</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI-75</measure>
    <time_frame>28 weeks</time_frame>
    <description>Psoriasis Area and Severity Index (PASI)‐75 response rate: the number of study participants with a PASI percent improvement from baseline of ≥ 75%. As no formalized disease severity assessment scoring exists for PRP, the PASI score was selected given the phenotypic overlap between psoriasis and PRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI-90</measure>
    <time_frame>28 weeks</time_frame>
    <description>PASI‐90 response rate: the number of study participants with a PASI percent improvement from baseline of ≥ 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>28 weeks</time_frame>
    <description>Dermatology Quality of Life Index - mean change before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA</measure>
    <time_frame>28 weeks</time_frame>
    <description>Physician Global assessment - mean change before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>PITYRIASIS RUBRA PILARIS</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a biopsy proven diagnosis of PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosentyx</intervention_name>
    <description>Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Informed subject consent will be obtained from those patients meeting the following
        inclusion criteria:

          -  Male and female patients 18 years or older.

          -  Clinical and/or histopathological diagnosis of PRP

          -  Candidate for systemic therapy (PASI ≥ 10)

          -  Body surface area of involvement ≥ 10%

          -  Good general health as confirmed by medical history

          -  Patients who are willing and capable of cooperating to the extent and degree required
             by the protocol; and

          -  Patients who read and sign an approved informed consent for this study

        Exclusion Criteria

        Patients are to be excluded based on the following criteria:

          -  Vulnerable study population

          -  Pregnant or nursing women

          -  Women planning a pregnancy within the study period

          -  Human immunodeficiency virus (HIV) positivity

          -  Known history of adverse reaction to Cosentyx

          -  Known history of hepatitis B, hepatitis C, or tuberculosis

          -  Personal or family history of inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason C Sluzevich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Sluzevich, MD</last_name>
      <phone>904-953-7214</phone>
      <email>sluzevich.jason@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jason C Sluzevich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jason Sluzevich MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pityriasis</mesh_term>
    <mesh_term>Pityriasis Rubra Pilaris</mesh_term>
    <mesh_term>Dermatitis, Exfoliative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

